Biomarkers of response and resistance to antiangiogenic therapy. - Wikidata - awgldk - TriplyDB

Biomarkers of response and resistance to antiangiogenic therapy.

Biomarkers of response and resistance to antiangiogenic therapy.

http://www.wikidata.org/entity/Q34673567

about

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors Biomarkers of cancer angioprevention for clinical studies Cancer imaging by optical coherence tomography: preclinical progress and clinical potential.Intertwined regulation of angiogenesis and immunity by myeloid cells Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics Novel molecular pathways in Gorham disease: implications for treatment Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model Molecular mechanisms and clinical applications of angiogenesis Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis (18)F-fluoromisonidazole kinetic modeling for characterization of tumor perfusion and hypoxia in response to antiangiogenic therapy.Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Phase I study of pazopanib plus TH-302 in advanced solid tumors.Simultaneous determination of labile proton concentration and exchange rate utilizing optimal RF power: Radio frequency power (RFP) dependence of chemical exchange saturation transfer (CEST) MRI.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Genetics of glioblastoma: a window into its imaging and histopathologic variability.Bevacizumab and breast cancer: current therapeutic progress and future perspectives Molecular mechanisms of resistance to tumour anti-angiogenic strategies Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.CXCR7 expression disrupts endothelial cell homeostasis and causes ligand-dependent invasion.

P2860

Q21183974-9F9CFEA1-F561-4373-ADDD-4E3C291E733F Q26752838-B056416A-AC88-4B54-ABB8-FD97843110B8 Q26773795-25C24589-3256-4170-BCBD-B1255A88009F Q26774580-6A6C4583-F41B-4B44-96F2-0B83FCC652B0 Q26823084-B57DDD56-6B19-4340-9655-3D4B1ABA4F69 Q26830418-69FCB820-48C0-4778-86EC-8D1F1FF4FB37 Q26996793-384F0115-4470-43D2-BBB7-48D02E44792A Q26998543-69420543-0F48-498B-BCA5-862B71F50B43 Q27005629-190B16DB-973A-4273-9F04-B459F0978DAC Q27021470-07A75FE9-EB6F-49DA-8DE9-1C350E0C5925 Q27026936-24D3F9F0-4FA8-4658-9AAE-E9271DA21FDC Q27346895-495C1AFD-D2B2-4CDE-87CE-265871992228 Q28081431-22D0E795-851A-4D56-98A2-4A17785031C3 Q28728593-E0332B97-C3C4-4D1F-ABFC-3EE4CAAC59BE Q28732214-BE2E1F1B-112F-4719-AEAA-311E513A79AE Q28742242-3106F4A4-4E61-400B-ABFB-948B844EDC0F Q29547314-D7DC9B91-31CA-41CA-BC09-EC308761356E Q30275254-C2BF3FF0-8795-49C5-AED4-D2651BF85949 Q30300114-680DF2EB-06C7-4611-9C25-D80D438E5BE7 Q30359059-63F65600-8043-4130-94AC-2A139E5163FE Q30388655-492D80C4-6CD1-40E2-A6FF-297D8831B946 Q30455820-54FD6AD4-C369-4A26-80AE-E9D3FC17F139 Q30469815-99867F82-CD47-4309-B0E3-492AC726CD9C Q30471456-8B5AAE08-208F-4B43-9C45-780200F30B5D Q30493217-42D1B8D2-5DD0-46C4-BEF9-4BC22D2FD019 Q30537414-61BF437B-10C5-45CE-9BC2-221B188D04EA Q30542073-D65482CC-46C1-4AB5-821C-89EC9EA0E4E4 Q30651792-CC611960-4497-477B-AD7F-447B54BB4992 Q30804219-6EE7EBC1-D148-4F35-8EA8-FD64060274E4 Q32179417-D3AEA8BE-3926-43A1-9E64-901D6C458079 Q33411581-9557BC4B-6A4B-4DAA-80A3-839D8EAED668 Q33426958-ED6829B5-EE58-4241-A1BA-6E353BFF3A1F Q33439635-B10FF281-F2AE-46F8-84CA-48A73E907AC3 Q33516294-46CD7171-4C15-4980-BFDD-DB5059076752 Q33587106-5E54716C-762B-467C-9FB9-761826C41ABC Q33620506-40BA1376-1F25-4041-B203-C0FD0069B751 Q33640753-87D1B198-EBBD-479C-82D1-DC19547EF853 Q33718025-5FAC0902-768D-42E7-8E83-98932DE73933 Q33721539-2FB8EEC7-6C1D-4066-A72E-FBE17BE0EE5E Q33728182-9FED6D1A-4D10-47C5-9AAA-4C121C79B4ED

P2860

Biomarkers of response and resistance to antiangiogenic therapy.

http://www.wikidata.org/entity/Q34673567

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Biomarkers of response and resistance to antiangiogenic therapy.

@ast

Biomarkers of response and resistance to antiangiogenic therapy.

@en

Biomarkers of response and resistance to antiangiogenic therapy.

@nl

type

label

Biomarkers of response and resistance to antiangiogenic therapy.

@ast

Biomarkers of response and resistance to antiangiogenic therapy.

@en

Biomarkers of response and resistance to antiangiogenic therapy.

@nl

prefLabel

Biomarkers of response and resistance to antiangiogenic therapy.

@ast

Biomarkers of response and resistance to antiangiogenic therapy.

@en

Biomarkers of response and resistance to antiangiogenic therapy.

@nl

P1433

Q34673567-D836D52D-E5E2-4096-99C6-D75117072F5B

P1476

Q34673567-2E561052-F610-4232-9494-4D1E4C8D2F76

P2093

Q34673567-1F9A6475-86C1-4773-8256-4C260F9EACE6

Q34673567-20F29B10-9529-4608-A731-6768D2B2B659

Q34673567-250361C6-A75C-40C7-A850-6C3398B0728F

Q34673567-DACD52C9-CF9B-4A8F-A1AC-1C3D5FA087BC

Q34673567-E0478903-1CB7-472D-AA07-607527BE06BC

Q34673567-E62C8E88-D5BC-4CAC-AB13-9D60EFD8F077

Q34673567-F54138CB-8309-4C9A-B776-9619AFE5F2E3

Q34673567-F6EE9D6E-7A4E-4146-9393-766F5F9E81DB

P2860

Q34673567-02AA8271-0E3A-4529-AB42-43D5BFE184D3

Q34673567-0988F5AA-BFE4-43A3-AB49-D405009F616B

Q34673567-0A1E4A14-64ED-4014-96F3-79BDDC5FCCF7

Q34673567-0C7E1AC8-DB15-4638-A154-B8AE2FC946C5

Q34673567-13FC92DF-64B2-44D6-862D-A5A0E24254CE

Q34673567-1511BE27-A35C-4D5C-8F26-88E1C4CE78FF

Q34673567-1539C761-C6D7-4D14-99B3-84C41B6B0AF6

Q34673567-187ACC9C-4B8D-47AD-9202-42A8B725B0ED

Q34673567-23A3EB4D-F352-4593-A540-B953E934B44B

Q34673567-292ED621-1852-444B-8E62-EF99B2FA263E

P304

Q34673567-B5AB6BF2-7DAD-4070-976B-7A4CBFC2A0BC

P31

Q34673567-02657A9E-5328-4178-9950-414799F8722D

P356

Q34673567-2AEF3266-5D61-4806-80BF-FF3E51F6C98B

P407

Q34673567-8AA6E772-FEB7-4A32-B99E-067B22DE97DB

P433

Q34673567-9AD812AA-32AC-4E93-8BD9-A67C5AF8C09F

P478

Q34673567-A149015F-A35B-495B-9378-961C7D217301

P577

Q34673567-D4541E37-042C-4353-98C8-ECA530F87CC5

P5875

Q34673567-465571BD-1C9D-43F9-9E9D-BC3268E43EC6

P698

Q34673567-53736D78-ACCB-4DB0-B8FF-7A9DC978B93F

P921

Q34673567-64411415-C794-4598-8ED5-15C63C86F067

P932

Q34673567-EB989974-05A0-40FD-92AA-F6287E8366B8

P356

NRCLINONC.2009.63

P1433

Nature Reviews Clinical Oncology

P1476

Biomarkers of response and resistance to antiangiogenic therapy.

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Christopher G Willett

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

Dushyant V Sahani

http://www.w3.org/2001/XMLSchema#string

Jay S Loeffler

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Tracy T Batchelor

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Angiogenesis in cancer and other diseases

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

P304

327-338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2009.63

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26254622

http://www.w3.org/2001/XMLSchema#string

P698

19483739

http://www.w3.org/2001/XMLSchema#string

P921

P932

3057433

http://www.w3.org/2001/XMLSchema#string